W. Clark

1 month ago | healio.com | W. Clark |Holly Liptak |Christine Klimanskis

KOLOA, Hawaii — In this expert perspective from Hawaiian Eye 2025, W. Lloyd Clark, MD, discusses the use of aflibercept 8 mg in the treatment of retinal vein occlusion. Clinical trial data support the use of higher-dose VEGF inhibition, he said. “I’m very excited about these clinical trial results, and as we move forward into 2025, I’m hopeful that we’ll have this treatment option available to us to improve clinical outcomes with retinal vein occlusion,” Clark said.

2 months ago | hcplive.com | W. Clark |Connor Iapoce

Aflibercept 8 mg (EYLEA HD) achieved positive results at 3 years among patients with neovascular (wet) age-related macular degeneration (nAMD) in an extension study of the Phase 3 PULSAR trial.1Announced by Regeneron Pharmaceuticals on February 8, 2025, these findings, presented at Angiogenesis, Exudation, and Degeneration 2025, revealed most patients treated with aflibercept 8 mg continued to experience improvements in vision and anatomy, with extended dosing intervals.

2 months ago | hcplive.com | W. Clark |Connor Iapoce

Positive results from the Phase 3 QUASAR trial demonstrate the noninferiority of aflibercept 8 mg (EYLEA HD) administered every 8 weeks to aflibercept 2 mg (EYLEA) dosed every 4 weeks for treating macular edema secondary to retinal vein occlusion (RVO).1Announced by Regeneron Pharmaceuticals on February 8, 2025, these findings, presented at Angiogenesis, Exudation, and Degeneration 2025, will support the submission of a supplemental Biologics License Application (sBLA) in Q1 2025.